H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $53 from $49 and keeps a Buy rating on the ...

Highlight,Sector Focus,: BridgeBio Pharma operates in the biopharmaceutical sector, with a focus on genetic conditions and oncology.,Insider Actions,: Notable insider share transactions have been ...

The treatment strategy for congenital adrenal hyperplasia is burdensome and had not changed in more than 70 years until the ...

Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that tafamidis ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

BridgeBio and BMS first started working together on studies of the drug combination in 2021, focusing on first- and second-line treatment of KRAS-positive non-small cell lung cancer (NSCLC).

The FDA has approved BridgeBio Pharma's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market showdown with its larger rival Pfizer.

Piper Sandler analyst Biren Amin maintained a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report) today and set a price target of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At close: April 17 at 4:00:02 PM EDT ...